Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.37 |
| ▸ | Q9HBH1 | 1/20 | 0.37 | |
| ▸ | CALCRL | Q16602 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 10/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25364326 | 0.91 | FURIN (0.36) | CTSLFURINROCK2 | |
| SCHEMBL25438103 | 0.90 | CTSL (0.41) | CTSLKLKB1PDFCALCRLFURIN | |
| SCHEMBL25361835 | 0.84 | FURIN (0.34) | FURIN | |
| SCHEMBL26026944 | 0.84 | SIRT5 (0.38) | CTSLKLKB1FURINROCK2 | |
| SCHEMBL26027087 | 0.83 | FURIN (0.40) | CTSLKLKB1FURINROCK2PLG | |
| SCHEMBL25709382 | 0.82 | FURIN (0.40) | CTSLFURINROCK2 | |
| SCHEMBL26027085 | 0.82 | KLKB1 (0.43) | CTSLKLKB1FURINROCK2MMP3 | |
| SCHEMBL25363108 | 0.82 | FURIN (0.38) | FURINROCK2 | |
| SCHEMBL24390287 | 0.82 | FURIN (0.38) | CTSLKLKB1FURINROCK2 | |
| SCHEMBL25363100 | 0.82 | FURIN (0.38) | FURINROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | CTSL 1742/4885KLKB1 2157/4885PDF 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.